Výsledky vyhledávání - "Valentina Sterlin"

Abstract P6-18-30: Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)

Autor: Chau T. Dang, Renjing Wang, Diana Lake, J. Baselga, Valentina Sterlin, S Wong, Jasmeet Chadha Singh, M Goldstein, Larry Norton

Publikováno v: Cancer Research. 79:P6-18

Background: Neratinib (N) is a potent irreversible inhibitor of HER1, HER2, and HER4 and has been shown to have antitumor activity in patients (pts) with human epidermal growth factor receptor 2 (HER2) - positive breast cancer. A previous study of co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25e1433c516d09b8b329afb3e031ace9
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-30

Zobrazit plný text záznamu

Abstract P6-20-03: Tumor epichaperome expression using 124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)

Autor: ME Moynahan, Gabriela Chiosis, Monica Fornier, Tony Taldone, S. Patil, S Khoshi, W. Ma, Shanu Modi, Elizabeth A. Comen, Jason S. Lewis, J. Bromberg, Valentina Sterlin, Mark Dunphy, Larry Norton, Komal Jhaveri, Renjing Wang, Anna Rodina

Publikováno v: Cancer Research. 79:P6-20

Background: The epichaperome is a new cancer target required for tumor survival (Joshi et al. Nature Reviews Cancer 2018). PU-H71 is a synthetic, purine scaffold epichaperome inhibitor that binds to the ATP-binding site of HSP90 specifically when HSP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7316d0d4bc2ea75ad703b3ff3d3a7242
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-03

Zobrazit plný text záznamu

Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)

Autor: Alexia Iasonos, Gary A. Ulaner, Michael F. Berger, Alex Morozov, Stephen Zamora, Teresa Gilewski, José Baselga, Mary Ellen Moynahan, Valentina Sterlin, Christina Coughlin, Nancy Sklarin, Sarat Chandarlapaty, Monica Fornier, Shanu Modi, Maura N. Dickler, Clifford A. Hudis, Joy Ero, Neal Rosen, Payal Deepak Shah

Publikováno v: Journal of Clinical Oncology. 33:590-590

590 Background: HER2+ breast cancer is driven by HER2/HER3/PI3K signaling. Single agent targeted therapy (tx) is limited by redundant mechanisms of pathway activation and feedback loops; preclinica...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15e1b4f0c15c1d5676d2b2534d06d5db
https://doi.org/10.1200/jco.2015.33.15_suppl.590

Zobrazit plný text záznamu

Abstract OT3-1-05: Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer

Autor: Stephen Zamora, Mary Ellen Moynahan, Valentina Sterlin, Sarat Chandarlapaty, Shanu Modi, Gary A. Ulaner, Payal Deepak Shah, Maura N. Dickler, Clifford A. Hudis, José Baselga, Alexia Iasonos

Publikováno v: Cancer Research. 75:OT3-1

Background: Breast cancers that overexpress the human epidermal growth factor receptor 2 (HER2+) are driven by HER2/HER3/PI3K signaling. Single agent therapy against this pathway is only modestly effective due to redundant mechanisms of pathway activ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c84e4e4a7932073a95f94e303651deb
https://doi.org/10.1158/1538-7445.sabcs14-ot3-1-05

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání